<DOC>
	<DOCNO>NCT01783522</DOCNO>
	<brief_summary>This randomized phase II trial study glutamine prevent peripheral neuropathy patient multiple myeloma receive bortezomib . Glutamine may help prevent peripheral neuropathy patient receive chemotherapy</brief_summary>
	<brief_title>Glutamine Preventing Peripheral Neuropathy Patients With Multiple Myeloma Receiving Bortezomib</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Estimate objective effect size glutamine compare placebo prophylactic intervention prevent bortezomib-induced peripheral neuropathy multiple myeloma patient 4 month first dose study drug . SECONDARY OBJECTIVES : I . Estimate whether glutamine delay prevents onset worsen neuropathy determine National Cancer Institute ( NCI ) -Common Terminology Criteria Adverse Events ( CTCAE ) v4.03 criterion . II . Determine glutamine may improve adherence bortezomib therapy . III . Assess response rate ( RR ) clinical benefit response rate ( CBR ) accord uniform international response criterion modify European Group Blood Marrow Transplantation ( EBMT ) criterion . IV . Determine glutamine may improve quality life ( QOL ) 4 month . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive glutamine orally ( PO ) twice daily ( BID ) . Courses repeat every 28 day 4 month absence disease progression unacceptable toxicity . ARM II : Patients receive placebo PO BID . Courses repeat every 28 day 4 month absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients diagnosis multiple myeloma receive bortezomib dose 1.3mg/m2 SQ weekly No evidence severe preexist peripheral neuropathy , NCICTCAE v4.03 = &lt; 2 Performance status = &lt; 2 Eastern Cooperative Oncology Group ( ECOG ) performance scale Concurrent use thalidomide , vincristine , platinum compound , agent know cause significant neuropathy ( concurrent lenalidomide allow ) Hospitalization clinical evidence active infection manifest recurrent fever , positive blood culture result , require intravenous antibiotic therapy Inadequate liver renal function liver transaminases 3x upper limit normal Glomerular filtration rate ( GFR ) accord CockcroftGault &lt; 30 mL/min Uncontrolled congestive heart failure Uncontrolled mood disorder Fasting blood glucose &gt; 150mg/dL blood sugar ( nonfasting ) &gt; 200mg/dL history diabetes . Uncontrolled diabetes HgA1C great 7 % last evaluation . Seizure disorder Monosodium glutamate ( MSG ) allergy soy allergy Life expectancy shorter 3 month base clinical laboratory parameter investigator 's opinion Uncorrected Vitamin B12 folate deficiency last evaluation . Use counter ( OTC ) supplement one multivitamin tablet day Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>